CASE REPORT

Acute Liver Injury Due to T-cell Infiltration into the Liver as an Initial Clinical Finding of Adult T-cell Leukemia/Lymphoma

Keisuke Kakisaka¹, Yuji Suzuki¹, Shugo Kowata², Shigeki Ito² and Yasuhiro Takikawa¹

Abstract:
Acute liver injury (ALI) has been rarely reported as a clinical finding of adult T-cell leukemia/lymphoma (ATLL). A 74-year-old Japanese female patient who was histologically diagnosed as having autoimmune hepatitis (AIH) one year earlier, showed elevations in her aminotransferase and total bilirubin levels, and this was considered to be an exacerbation of AIH. Liver biopsy revealed interface hepatitis. Because atypical lymphocytes and human T-cell leukemia virus 1 immunoglobulin G antibody were positive, the patient was diagnosed to have ATLL. The biopsy revealed CD4+ and CD8+, but not CD20+ lymphocytes. Thus, the ALI in the patient was due to T-cell infiltration into the liver, and not due to an exacerbation of AIH.

Key words: ATLL, acute liver injury, AIH, HTLV-1

(Intern Med 60: 2431-2436, 2021) (DOI: 10.2169/internalmedicine.6793-20)

Introduction

Adult T-cell leukemia/lymphoma (ATLL) is a rare and distinct T-cell malignancy associated with human T-cell leukemia virus 1 (HTLV-1) infection. HTLV-1 is endemic in Japan, the Caribbean basin, South America, and Central Africa (1). ATLL presents with diverse clinical features and it has a poor prognosis. It can be divided in four clinical subtypes: acute, chronic, smoldering, and lymphoma types (2). Although several studies have reported that diffuse infiltration of leukemia cells induce acute liver failure (3, 4), acute liver injury has rarely been reported as an initial clinical finding of ATLL. We herein report that acute liver injury presented as a first clinical finding in an ATLL patient who was previously diagnosed to have autoimmune hepatitis (AIH).

Case Report

A 74-year-old Japanese female patient who was histologically diagnosed to have AIH one year earlier [score of Revised Original Scoring System of the International Autoimmune Hepatitis Group (5) before treatment was 15: probable (Table 1)] and had thus been treated with 5 mg prednisolone to sustain normal liver enzyme levels after liver biopsy (Fig. 1, 2A), complained of body weight loss, appetite loss, and general fatigue. Laboratory data showed elevations in aminotransferase and total bilirubin, although there was no evidence for disseminated intravascular coagulation, phagocytic syndrome, or infection. However, atypical lymphocytes were observed in a peripheral blood smear, and an elevation of CD4 to CD8 ratio was also detected due to an increase in CD8+ lymphocytes in the peripheral blood. Notably, the levels of markers associated with viral infection were not elevated. Elevated levels of soluble interleukin-2 receptor were detected after admission. Upon comparing computed tomography (CT) scans performed at the time of AIH diagnosis to those obtained at the time of admission, imaging at the time of admission revealed swelling of the intraabdominal lymph nodes and hepatomegaly, but there was no evidence of obstructive jaundice (Fig. 3). A liver biopsy performed at admission re-
revealed lymphocyte infiltration into the portal tract and interface hepatitis (Fig. 4A). We considered that the acute liver injury was an exacerbation of AIH. The liver injury improved after the dose of prednisolone was increased to 0.5 mg/kg. After increasing the dosage of prednisolone, atypical lymphocytes were detected in a routine complete blood count analysis. An examination of a peripheral-blood smear revealed a few atypical lymphocytes which were medium-sized with pronounced nuclear pleomorphism. Serological tests were positive for HTLV-1 immunoglobulin G antibody. A flowcytometric analysis showed atypical lymphocytes that were positive for T-cell markers CD2, CD3, CD4, and CD5, with the co-expression of CD25, and negative for CD8. Monoclonal integration of HTLV-1 was recognized by the Southern blot method. Re-evaluation by CT scans revealed multiple lymphadenopathy in thoracic and abdominal area without an enlargement of the liver. Overall, these findings are consistent with the diagnosis of ATLL (acute type). At 1 month after making a diagnosis, she developed dyspnea due to massive pleural effusion by ATLL cell invasion to the mediastinal region. Intensified chemotherapy was started using a CHOP-like regimen. Four months after the start of chemotherapy, she died of intracranial metastasis of ATLL. Informed consent for this case report was obtained from the patient and her daughter.

Liver tissue of the second biopsy was compared with that of the first used for the initial diagnosis of AIH. Both tissues showed interface hepatitis and the infiltration of both CD4+ and CD8+ lymphocytes (Fig. 2C, D, 4C, D). Although CD20+ lymphocytes existed in the first biopsy, these cells were not observed in the second biopsy (Fig. 2B, 4B). Based on these findings, the acute liver injury in the patient was deemed to be due to T-cell infiltration into the liver, and not due to an exacerbation of AIH.

### Table 1. International Autoimmune Hepatitis Group Score in the Present Case.

| International AIH group score |       |       |       |
|------------------------------|-------|-------|-------|
| Sex                          | Female| 2     |       |
| ALP/AST                      | <1.5  | 2     |       |
| IgG                          | 1.0 - 1.5 | 1     |
| ANA                          | <1:40 | 0     |       |
| AMA                          | Negative | 0     |
| Virus marker                 | Negative | 3     |
| Drug exposure                | Negative | 1     |
| Alcohol intake               | <25 g/day | 2     |
| Histological findings        |       |       |       |
| Interface hepatitis          | Positive | 3     |
| Infiltration of plasma cell  | Positive | 1     |
| Total                        |       | 15    |       |

ALP: alkaline phosphatase, ANA: anti-nuclear antibody, AMA: anti-mitochondrial antibody, AST: aspartate transaminase, IgG: immunoglobulin G

---

**Figure 1.** Clinical course of the present case. The upper line chart shows serial changes in immunoglobulin G. The bottom line chart shows serial change in alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and total bilirubin (T-Bil). The black arrowheads indicated the dates of liver biopsy. The black boxes indicate the dosage of prednisolone (PSL).
Figure 2. Histological findings of the first liver biopsy. A: Hematoxylin and Eosin staining section; B, C and D: Immunohistochemistry for CD20 (B), CD4 (C), and CD8 (D) using appropriate antibodies. These slides were serial sections. Mild inflammation and interface hepatitis were found in the portal tract (A). CD20+ cells (B), CD4+ cells (C) and CD8+ cells (D) were detected in the portal tract.

Table 2. The Laboratory Data of the Patient in the Admission.

| Hematology       | Fibrosis marker   |
|------------------|-------------------|
| WBC 6.41 × 10^3/mL | Type IV collagen7S 7.2 ng/mL |
| LUC 3.3 %        | Blood coagulation |
| Aty. lymph +     |                   |
| RBC 4.10 × 10^9/mL | PT-INR 0.95     |
| Hb 12.9 g/dL     | APTT 34.2 sec.   |
| Plt 212 × 10^3/mL | Fib 316 mg/dL    |
| Renal function   |                   |
| BUN 10.3 mg/dL   |                   |
| Cre 0.69 mg/dL   |                   |
| Blood chemistry  |                   |
| T-Bil 4.5 mg/dL  | CMV IgM (+)      |
| AST 856 IU/L     | EBV VCA IgM <10   |
| ALT 599 IU/L     | EBV VCA IgG 40    |
| LDH 821 IU/L     | EBV EBNA 10       |
| γ-GTP 93 IU/L    |                   |
| ALP 508 IU/L     | sIL2R 3,920 U/mL |
| Albumin 3.6 g/dL |                   |
| Na 138 mmol/L    | CD3CD4 56.2 %    |
| Ca 9.2 mg/dL     | CD3CD8 10.4 %    |
| IgG 918 IU/L     | CD4/CD8 ratio 5.43|
| IgM 42 IU/L      |                   |
| CRP 0.48 mg/dL   |                   |

ALP: alkaline phosphatase, ALT: alanine aminotransferase, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, BUN: blood urea nitrogen, CD: cluster designation, CMV: cytomegalovirus, Cre: creatinine, CRP: C-reactive protein, EB: Epstein–Barr virus, Fib: fibrinogen, γ-GTP: γ-glutamyl transpeptidase, Hb: hemoglobin, Ig: immunoglobulin, Plt: platelets, PT-INR: prothrombin time international ratio, RBC: red blood cells, sIL2R: soluble interleukin-2 receptor, T-Bil: total bilirubin, WBC: white blood cells.
**Figure 3.** Computed tomography imaging at the time of AIH diagnosis and at the time of admission. The liver volume assessed at the time of AIH (A) and at admission (C). Intraabdominal lymph node assessment at the time of AIH (B) and at admission (D). The arrow heads indicated lymph nodes with swelling.

**Figure 4.** Histological findings of the second liver biopsy. A: Hematoxylin and Eosin staining section; B, C and D: Immunohistochemistry for CD20 (B), CD4 (C), and CD8 (D). These slides were serial sections. Mild interface hepatitis and infiltration of cells were found in the portal tract (A). There were few CD20+ cells (B), CD4+ cells (C) and CD8+ cells (D) were abundantly found in the portal tract and liver parenchyma.
Acute liver injury in the present case was due to T-cell infiltration into the liver, as CD20+ cells were absent in the liver tissue (Fig. 4B, C, D). A liver biopsy at the time of the diagnosis of AIH showed abundant infiltration of CD20+ cells at the portal tract (Fig. 2B), which is known to be evidence of active AIH (6, 7). Thus, the elevation in the liver enzyme level in the present case was not mediated by a humoral mechanism, which is believed to be involved in the pathophysiology of AIH (8). As there was no overt evidence of ATLL when the acute liver injury appeared, we could not conclude that leukemia cells mediated the liver injury at the time of the second biopsy. However, the patient was diagnosed to have acute-type ATLL only two months after the second biopsy, and symptoms sustained until the time of ATLL diagnosis. Therefore, we consider that acute liver injury can be a clinical finding of ATLL.

The pathophysiology of liver injury associated with ATLL has been rarely studied. In contrast, HTLV-1-associated myelopathy (HAM) has been researched and the hypothetical pathophysiology has been reported by others (9). The hypothetical mechanism of HAM is as follow. HTLV-1-specific cytotoxic T lymphocytes (CTL) are stimulated by the HTLV-1 antigens and accumulate in the spinal cord. These CTLs recognize viral antigens on the HTLV-1-infected CD4+ T cells which infiltrate into the spinal cord, resulting in the secretion of proinflammatory cytokine. HTLV-1-specific CTLs lead to apoptosis of neural cells in the nerve system. As a result, the nervous system is destructed. Although there is no evidence associated with a similar mechanism in this case, this hypothetical mechanism may have played a role in this case.

Prednisolone improved the liver injury caused by T-cell infiltration in this case. We consider two hypothetical mechanisms. First, prednisolone might induce apoptosis in CD4+ and CD8+ cells (10), and liver injury would have improved after the infiltrated cells had decreased. Second, prednisolone might suppress the autoimmune response (11, 12). HTLV-1 infection is reportedly associated with autoimmune diseases, as HTLV-1 modifies the behavior of CD4+ cells and alters their cytokine production (13, 14). Prednisolone induces CD4+ and CD8+ cell populations, which synthesize high levels of IL-10, but reduces the amounts of autoimmune disease-promoting IL-4 and IL-5 (12). As a result, prednisolone may reduce HTLV-infection associated with liver injury.

A misdiagnosis had occurred in this case during the initial assessment of the patient, due to the presence of elevated levels of transaminase. Acute liver failure occurring due to infiltration of the liver by malignant cells is well-known, and leukemia or lymphoma are common causes of malignant infiltration of the liver (15). Thus, we hypothesized that malignant infiltration of the liver could be considered for the differential diagnosis of patients with acute liver failure. However, in this study, we did not predict ATLL as a potential cause of ALI since the patient had originally been diagnosed with AIH. This case study highlighted the need to perform a differential diagnosis of patients with ALI, even in patients previously diagnosed with a chronic liver disease.

A prior study had reported that upon comparison of the frequency of liver infiltration between ATLL and non-Hodgkin lymphoma patients, ATLL was found to be a more common etiology of liver infiltration (16). Additionally, when a patient presents with multiple lymphadenopathy and hepatomegaly, ATLL, rather than non-Hodgkin lymphoma should be suspected.

In Japan, the east coast of northern Tohoku as well as Kyushu island are known to be regions with a high prevalence of HTLV-1 infection. After making a diagnosis of AIH, we enquired the patient about her and her parents’ place of birth. The patient and her parents were not born in the regions with high prevalence of HTLV-1. However, the patient was breastfed by a woman who was born in such a region but had no relationship with the patient, since the patient’s mother died after the birth of the patient. Although there was no information regarding the HTLV-1 infection status of the woman who breastfed the patient, we suspected that the woman might have been infected with HTLV-1. The anamnesis detailed above was obtained after diagnosis of ATLL. Since HTLV-1 transmission mainly occurs during breastfeeding from a mother infected with HTLV-1, we enquired the patient about her nursing and family history as well as the place of her birth once the patient was suspected to be infected with HTLV-1.

There are some limitations associated with this case study. We did not confirm how infiltrated T-cells in the liver injured the hepatocytes, and we did not evaluate any cytokines. Thus, precisely how prednisolone improved liver injury in this case remains unclear. As mentioned above, HTLV-1 infection is associated with autoimmune disease. However, whether the pre-existing AIH in this case was associated with HTLV-1 infection remains unknown. As AIH has never been reported as a complication of HTLV-1 infection, we suspect that AIH was not associated with HTLV-1 infection.

The authors state that they have no Conflict of Interest (COI).

Financial Support
This study was supported in part by a Health Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan as a project by the Intractable Hepato-Biliary Diseases Study Group of Japan.

References
1. Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23: 577-589, 2010.
2. Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci 106:
3. Powell N, Rusli F, Hubsccher SG, Karanth M, Mutimer D. Adult T-cell leukemia presenting with acute liver failure. Leuk Res 30: 1315-1317, 2006.
4. Kawamura E, Habu D, Kurooka H, et al. Adult T-cell leukemia blast crisis in a patient with acute liver failure. Indian J Gastroenterol 25: 49, 2006.
5. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938, 1999.
6. Beland K, Marceau G, Labardy A, Bourbonnais S, Alvarez F. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology 62: 1511-1523, 2015.
7. Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 42: 926-930, 2008.
8. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35: 890-897, 2002.
9. Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol 3: 389, 2012.
10. Purton JF, Monk JA, Liddicott DR, et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 173: 3816-3824, 2004.
11. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 202: 1459-1463, 2005.
12. Richards DF, Fernandez M, Caulfield J, Hawrylowicz CM. Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production. Eur J Immunol 30: 2344-2354, 2000.
13. Nakamaru Y, Ishizu A, Ikeda H, et al. Immunological hyperresponsiveness in HTLV-I LTR-env-pX transgenic rats: a prototype animal model for collagen vascular and HTLV-I-related inflammatory diseases. Pathobiology 69: 11-18, 2001.
14. Pinheiro SR, Lana-Peixoto MA, Proietti AB, Orefice F, Lima-Martins MV, Proietti FA. HTLV-I associated uveitis, myelopathy, rheumatoid arthritis and Sjogren’s syndrome. Arq Neuropsiquiatr 53: 777-781, 1995.
15. Rich NE, Sanders C, Hughes RS, et al. Malignant infiltration of the liver presenting as acute liver failure. Clin Gastroenterol Hepatol 13: 1025-1028, 2015.
16. Yamada Y, Kamihira S, Murata K, et al. Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin’s lymphoma. Leuk Lymphoma 26: 327-335, 1997.